TScan Therapeutics Inc TCRX.OQ TCRX.O is expected to show a rise in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Waltham Massachusetts-based company is expected to report a 88.8% increase in revenue to $1.98 million from $1.05 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for TScan Therapeutics Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 80.7% above its last closing price of $1.16
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.28 | -0.28 | -0.28 | Met | 0.2 |
Mar. 31 2025 | -0.29 | -0.29 | -0.26 | Beat | 9.1 |
Dec. 31 2024 | -0.27 | -0.27 | -0.30 | Missed | -9.6 |
Sep. 30 2024 | -0.29 | -0.29 | -0.25 | Beat | 13.1 |
Jun. 30 2024 | -0.28 | -0.28 | -0.28 | Met | 1 |
Mar. 31 2024 | -0.26 | -0.26 | -0.32 | Missed | -24.8 |
Dec. 31 2023 | -0.26 | -0.29 | -0.21 | Beat | 27.6 |
Sep. 30 2023 | -0.50 | -0.45 | -0.24 | Beat | 46.9 |
This summary was machine generated November 7 at 11:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)